RxDoctor Payments Data

Sarita Kansal, MD

Internal Medicine · West Seneca, NYNPI 1073556825

Payments from drug & device makers

$1,275in general payments, 2019–2025

Across 65 payments — averaging $19.62 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AstraZeneca$518
  • GSK$232
  • AbbVie$121
  • Pfizer$70
  • Amgen$69
  • Lilly USA, LLC$49
  • plus $216 from 9 others

What the payments were for

  • Food & beverage$1,275100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,275 in reported general payments places this provider in the 75th percentile of 9,771 internal medicine providers in New York.

See all internal medicine providers in New York

Medicare billing

Part B allowed, 2024
$39,475
Medicare patients
78
Services billed
501

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban56$74,518
Trelegy ElliptaFluticasone/Umeclidin/Vilanter67$65,464
TrulicityDulaglutide35$64,923
XareltoRivaroxaban20$30,697
JardianceEmpagliflozin22$25,444
OzempicSemaglutide15$21,082
MyrbetriqMirabegron12$10,685
Atorvastatin Calcium626$9,510
Fluticasone-SalmeterolFluticasone Propion/Salmeterol40$9,393
Combivent RespimatIpratropium/Albuterol Sulfate14$9,299
Metoprolol Succinate336$5,176
Amlodipine Besylate593$5,109
Repaglinide96$4,679
SynthroidLevothyroxine Sodium49$3,588
Levothyroxine Sodium222$3,253

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$70$74,51856 claims
GSKTrelegy Ellipta$232$65,46467 claims
Lilly USA, LLCTrulicity$49$64,92335 claims
Johnson & JohnsonXarelto$43$30,69720 claims
Novo NordiskOzempic$39$21,08215 claims
AbbVieSynthroid$121$3,58849 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 9,771 internal medicine providers in New York.

Other internal medicine in West Seneca

See the full list for New York

Where these figures come from

Is this you, or does something look wrong? →